BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,099 filers reported holding BAXTER INTL INC in Q1 2020. The put-call ratio across all filers is 0.81 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $217,826 | -14.6% | 6,512 | +9.1% | 0.00% | 0.0% |
Q1 2024 | $255,030 | +821.3% | 5,967 | +733.4% | 0.00% | – |
Q4 2023 | $27,681 | -96.3% | 716 | -96.1% | 0.00% | -100.0% |
Q1 2023 | $753,037 | -66.2% | 18,566 | -57.5% | 0.00% | -40.0% |
Q4 2022 | $2,227,746 | -66.2% | 43,707 | -64.3% | 0.01% | -61.5% |
Q3 2022 | $6,593,000 | +1118.7% | 122,407 | +1352.6% | 0.01% | +1200.0% |
Q2 2022 | $541,000 | -44.5% | 8,427 | -33.0% | 0.00% | 0.0% |
Q1 2022 | $975,000 | -67.5% | 12,574 | -64.0% | 0.00% | -50.0% |
Q4 2021 | $3,002,000 | -12.7% | 34,974 | -18.2% | 0.00% | -50.0% |
Q3 2021 | $3,440,000 | +54.6% | 42,774 | +54.8% | 0.00% | +33.3% |
Q2 2021 | $2,225,000 | +1077.2% | 27,638 | +1079.1% | 0.00% | +200.0% |
Q3 2020 | $189,000 | +243.6% | 2,344 | +268.6% | 0.00% | – |
Q2 2020 | $55,000 | -69.3% | 636 | -70.3% | 0.00% | -100.0% |
Q4 2019 | $179,000 | -31.2% | 2,139 | -28.0% | 0.00% | -50.0% |
Q3 2019 | $260,000 | +14.5% | 2,971 | +7.3% | 0.00% | 0.0% |
Q2 2019 | $227,000 | -32.0% | 2,769 | -45.5% | 0.00% | -33.3% |
Q4 2018 | $334,000 | +1987.5% | 5,077 | +2388.7% | 0.00% | – |
Q3 2018 | $16,000 | -89.9% | 204 | -92.2% | 0.00% | -100.0% |
Q2 2017 | $159,000 | +7.4% | 2,630 | -8.0% | 0.00% | 0.0% |
Q1 2017 | $148,000 | -52.6% | 2,858 | -36.5% | 0.00% | -75.0% |
Q2 2013 | $312,000 | – | 4,499 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |